The American journal of emergency medicine
-
The aim of this study was to determine the hemodynamic response and calculated shock index (SI=heart rate [HR]/systolic blood pressure [SBP]) in early acute blood loss. ⋯ A significant elevation in mean SI was observed in healthy volunteers after standing for 1 and 5 minutes. Although significant changes in HR and SBP were observed, these indices were still within "normal" limits. The SI may be more useful in early hemorrhage than either the HR or SBP alone.
-
Letter Case Reports
Injection of pyrethroids without significant sequelae.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure.
The Prospective Randomized Outcomes study of Acutely decompensated Congestive heart failure Treated Initially as Outpatients with Nesiritide (PROACTION) trial evaluated the safety of nesiritide administration in the emergency department in patients with decompensated heart failure. Patients (N=237) were treated for at least 12 hours with standard care plus either intravenous nesiritide or placebo. ⋯ Both treatment groups had similar incidences of symptomatic and asymptomatic hypotension. These data demonstrate that early administration of nesiritide in the emergency department is a safe and effective treatment of heart failure.
-
Randomized Controlled Trial Clinical Trial
Etomidate and midazolam for procedural sedation: prospective, randomized trial.
To evaluate whether there is a difference in the time of sedation and time to patient disposition in patients undergoing procedural sedation with etomidate and midazolam. ⋯ The use of etomidate compared with midazolam for procedural sedation provides a significant reduction in recovery time, without a reduction in time to patient disposition, while providing equal sedation quality.